Investor Relations

NEO:CYBN

view stock
Cybin is a leading biotech company in the psychedelic therapeutic sector. Our team is focused on the development of mental healthcare treatment with a single-minded goal to dramatically improve patient outcomes versus currently available pharmacotherapies. Our work includes the development of new drug molecules, with a focus on optimizing treatment outcomes through: innovative drug delivery systems, concurrent therapy regimens, and technology-drive patient analytics. Learn more about how we are working to revolutionize mental healthcare in our three pillar strategy.
NEO:CYBN

view stock

Invest in Cybin

1

phase 2 trial in 2021

C$

88

M

raised to date to progress m&a strategy and clinical trials

12

patent filings

10

Patent filings

2

phase 1 trials in 2021

C$

88

M

raised to date to progress
m&a strategy

Investor Presentation

Last updated: 04.25.2021
Cybin Inc. Corporate Presentation
Download presentation

2021 Financial Highlights and Business Update

Download

SEDAR Profile

Visit
Events
Date
Details
June 17, 2021
H.C Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond
July 13, 2021
Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
August 12, 2021
Canaccord Genuity's 41st Annual Growth Conference
press releases
6.11.2021

Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

Read more >
6.8.2021

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Read more >
6.2.2021

Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021

Read more >
read more

Corporate Governance

close

Our site uses cookies. Learn more about our privacy policy.

I accept the use of cookies